The review summarizes mechanistic plausibility (hormesis via redox signaling: Nrf2–Keap1, MAPK, autophagy) and case-level observations in asthma, COPD, sleep disorders/OSA, snoring, pneumonia, plus selected non-respiratory symptoms (e.g., chemotherapy-related fatigue) as preliminary signals that warrant trials.
Current annual cost burden (order of magnitude)
| Disease / condition | Best global/US anchor numbers (direct + indirect, where available) | What mainly drives the spend |
|---|---|---|
| Asthma | Global economic burden projected $1.41T in 2023 (value-of-statistical-life framework; includes medical + productivity + mortality valuation). (f1000research.com) | Drugs, exacerbations, productivity loss; severe asthma drives a disproportionate share. (tandfonline.com) |
| COPD | EU direct costs ≈ €38.6B/yr, ~56% of all EU respiratory spend; US costs ~$40B/yr and rising; global macro burden is “large” with major productivity losses. (FIRS) | Hospitalizations & exacerbations, disability/early retirement, prescriptions. (copd.efanet.org) |
| Obstructive Sleep Apnea (OSA) | US (2015): $149.6B/yr for undiagnosed OSA: $86.9B lost productivity, $26.2B motor-vehicle crashes, $6.5B workplace accidents, plus medical costs. (AASM) | Productivity loss dominates; accidents and cardiometabolic comorbidity are large secondary drivers. (PMC) |
| Community-acquired pneumonia / pneumococcal disease (adults) | Costs escalate sharply with age; studies document substantial per-case direct costs and national burdens (varies by country). (PLOS) | Hospitalization days, complications, and (in some regions) antimicrobial resistance. (PLOS) |
Why these particular diseases? They’re the ones where the review either reports observations (asthma, COPD, OSA/snoring, pneumonia) or proposes a plausible, testable redox mechanism for symptom reduction or faster recovery.
Drug side-effect costs you asked to include
Systemic corticosteroids (for flares):
Long-term use significantly raises fracture risk; fractures occur in 30–50% of chronic glucocorticoid users, with hip/vertebral events especially costly. US hip-fracture care alone runs into >$10–15B/yr (acute phases), with per-patient 1-year costs often in the $30k–$35k range (and higher in many datasets). Metabolic complications (hyperglycemia/diabetes, hypertension, weight gain) add further cost. (NCBI)
Statins → new-onset diabetes:
Meta-analyses show a ~9% relative increase in incident diabetes with statin therapy; new diabetes carries ~$12k/yr attributable medical costs per person in the US (average expenditures $19.7k/yr, of which ~$12k is the diabetes-attributable share). (PMC)
Implication: if a non-drug intervention reduces steroid exposure and/or helps some patients avoid polypharmacy, you trim not only “primary” disease costs but also iatrogenic costs (fractures, diabetes care, etc.).
Stakeholder impact if the method scales
- Public health systems / payors: fewer exacerbations, admissions, and ER visits → direct medical spend falls; productivity improves (large lever in OSA/asthma). In OSA alone, even tiny improvements in alertness cut crash and presenteeism costs quickly. (PMC)
- Pharmaceutical companies (respiratory/sleep-adjacent): headwinds in inhaled steroids/bronchodilators and some sleep-adjacent categories if real-world drug days decline. (Respiratory drug market ≈ $16.3B in 2023, growing to ≈$26B by 2031; bronchodilators ≈$23–36B range by 2033; sleep-apnea devices ≈ $7.6B in 2025). A durable shift to a non-drug adjunct dents TAM and growth trajectories. (consegicbusinessintelligence.com)
- Medical cannabis market: some substitution risk in indications where patients currently seek cannabis for sleep, anxiety, or respiratory comfort; the global medical cannabis market is sized in the $24–26B (2024–2025) range with rapid CAGR. If a low-dose singlet-oxygen routine becomes a mainstream, low-friction alternative for sleep/comfort, growth could slow at the margin. (databridgemarketresearch.com)
- The public / economy: fewer sick days and safer roads (OSA), faster pneumonia recovery, and less steroid exposure → more days at work, fewer injuries, lower out-of-pocket drug spend. In macro terms, a 1–2% shave on the biggest line items is already billions. (AASM)
A conservative “what-if” (so you can quote numbers without over-promising)
Assumption set (modest, defensible):
- Adoption among symptomatic patients reaches just 10% in each disease bucket.
- Among adopters, average 10% improvement on cost drivers we can plausibly affect (exacerbations/hospital days/accidents/productivity).
- We only count one lever per disease (so we don’t double-dip).
This is intentionally cautious and does not claim causality; it just sizes the prize if trials reproduce the review’s observational signals.
Back-of-envelope savings:
- Asthma (global): 10% adoption × 10% improvement × $1.41T ≈ $14.1B/yr avoided burden. (f1000research.com)
- COPD (EU, direct costs only): 10% × 10% × €38.6B ≈ €0.386B/yr direct-care savings (EU alone). Extrapolating similar fractions to US (~$40B/yr) would be ≈ $0.4B/yr. (FIRS)
- OSA (US, undiagnosed burden): 10% × 10% × $149.6B ≈ $1.50B/yr—mostly from productivity and accident reductions. (AASM)
- Pneumonia (adults): apply the same 10%×10% to national adult pneumococcal or CAP spend; in systems with high hospitalization rates this is non-trivial (country-specific math required). (PLOS)
Side-effect offsets (steroids/statins), illustrative:
- If reduced steroid days avert just 1,000 hip fractures worldwide (tiny fraction of annual events), at $30k–$35k per case you free $30–35M/yr, not counting long-term disability costs. (PMC)
- If fewer patients escalate to high-dose statins (or achieve dose reductions) and 1,000 cases of statin-associated diabetes are avoided, you protect roughly $12M/yr in attributable medical costs (US cost basis). (PubMed)
Sum those conservative skims and you’re comfortably into multi-billion-dollar annual global savings—before considering spillovers like reduced antimicrobial resistance pressure (if pneumonia recoveries shorten) or fewer steroid-triggered infections. (AMR is itself a multi-trillion risk by 2050). (The Guardian)
Where this rests on your review (for editors and skeptics)
- Documented observations: COPD reversal cases with normalized spirometry and medication discontinuation; OSA/snoring improvements; repeated pneumonia recovery anecdotes—each framed as hypothesis-generating.
- Mechanistic plausibility: low-dose ¹O₂ acting as a hormetic trigger—Nrf2/autophagy/inflammation set-point adjustments; plausible effects on mucociliary clearance and airway tone during sleep.
Bottom line (use this paragraph as a pull-quote)
If a low-risk, non-drug routine trims just 1–2% off today’s largest respiratory and sleep-related cost lines, you’re looking at billions saved each year globally—with gains mostly accruing to patients, employers, and public payors. The obvious losers are the drug and device categories whose revenues depend on chronic daily use (inhaled steroids/bronchodilators, some sleep-apnea hardware, and a sliver of medical cannabis demand). The thesis doesn’t need miracle effect sizes; even small, repeatable improvements in exacerbations, hospital days, and productivity move the needle at scale. (f1000research.com)
Sources (key ones you can cite publicly)
- Avraham Y. Low-Dose Singlet Oxygen as a Hormetic Agent (review: mechanisms + observational cases).
- Global asthma burden (2023 → 2050 projection). (f1000research.com)
- COPD economics (EU/US + global macro framing). (FIRS)
- OSA economics (US $149.6B; cost composition). (AASM)
- Pneumonia/pneumococcal adult burden studies. (PLOS)
- Steroids → fractures & metabolic events; fracture costs. (NCBI)
- Statins → diabetes risk; per-patient diabetes costs. (PMC)
- Market context: respiratory drugs, bronchodilators, sleep-apnea devices; medical cannabis. (consegicbusinessintelligence.com)
Leave a Reply